海辰药业跌2.12%，成交额5327.78万元，主力资金净流出92.90万元

Group 1 - The core viewpoint of the news is that Hainan Pharmaceutical's stock has experienced significant fluctuations, with a year-to-date increase of 189.48% but a recent decline of 19.24% over the last five trading days [1] - As of November 21, Hainan Pharmaceutical's stock price was 58.07 yuan per share, with a market capitalization of 6.968 billion yuan [1] - The company has seen a net outflow of 929,000 yuan in principal funds, with large orders showing a buy of 9.1799 million yuan and a sell of 11.4989 million yuan [1] Group 2 - Hainan Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, focuses on the research, production, and sales of chemical preparations, raw materials, and intermediates [2] - The main business revenue composition includes cardiovascular drugs (87.12%), antibiotics (5.69%), and other categories [2] - As of November 10, the number of shareholders was 22,100, a decrease of 2.84%, with an average of 3,709 circulating shares per person, an increase of 2.93% [2] Group 3 - Hainan Pharmaceutical has distributed a total of 161 million yuan in dividends since its A-share listing, with 18 million yuan in the last three years [3] - As of September 30, 2025, new institutional shareholders include several funds, with notable holdings from China Europe Enjoy Life Mixed A and Huazhang Medical Biological Stock Initiation A [3]